vs
ANI PHARMACEUTICALS INC（ANIP）とIDACORP INC（IDA）の財務データ比較。上の社名をクリックして会社を切り替えられます
IDACORP INCの直近四半期売上が大きい（$360.1M vs $247.1M、ANI PHARMACEUTICALS INCの約1.5倍）。IDACORP INCの純利益率が高く（12.1% vs 11.1%、差は1.0%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -4.2%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $-216.2M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -7.2%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
IDACORP, Inc.はアメリカ・アイダホ州に法人登録され、本社をボイシに置く電力持株会社です。1998年10月1日に設立され、傘下にアイダホパワー社、IDACORPフィナンシャル社、アイダウエストエナジー社を有し、電力供給、エネルギーサービス、関連金融事業を手がけています。
ANIP vs IDA — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $360.1M |
| 純利益 | $27.5M | $43.6M |
| 粗利率 | — | — |
| 営業利益率 | 14.1% | 14.9% |
| 純利益率 | 11.1% | 12.1% |
| 売上前年比 | 29.6% | -4.2% |
| 純利益前年比 | 367.5% | 15.1% |
| EPS（希薄化後） | $1.14 | $0.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $360.1M | ||
| Q3 25 | $227.8M | $526.4M | ||
| Q2 25 | $211.4M | $449.3M | ||
| Q1 25 | $197.1M | $411.1M | ||
| Q4 24 | $190.6M | $375.9M | ||
| Q3 24 | $148.3M | $532.5M | ||
| Q2 24 | $138.0M | $442.6M | ||
| Q1 24 | $137.4M | $417.9M |
| Q4 25 | $27.5M | $43.6M | ||
| Q3 25 | $26.6M | $124.4M | ||
| Q2 25 | $8.5M | $95.8M | ||
| Q1 25 | $15.7M | $59.6M | ||
| Q4 24 | $-10.3M | $37.9M | ||
| Q3 24 | $-24.2M | $113.6M | ||
| Q2 24 | $-2.3M | $89.5M | ||
| Q1 24 | $18.2M | $48.2M |
| Q4 25 | 14.1% | 14.9% | ||
| Q3 25 | 15.9% | 27.5% | ||
| Q2 25 | 6.6% | 22.4% | ||
| Q1 25 | 13.3% | 13.4% | ||
| Q4 24 | -2.3% | 11.0% | ||
| Q3 24 | -13.8% | 25.1% | ||
| Q2 24 | 3.7% | 23.3% | ||
| Q1 24 | 14.8% | 11.9% |
| Q4 25 | 11.1% | 12.1% | ||
| Q3 25 | 11.7% | 23.6% | ||
| Q2 25 | 4.0% | 21.3% | ||
| Q1 25 | 8.0% | 14.5% | ||
| Q4 24 | -5.4% | 10.1% | ||
| Q3 24 | -16.3% | 21.3% | ||
| Q2 24 | -1.7% | 20.2% | ||
| Q1 24 | 13.2% | 11.5% |
| Q4 25 | $1.14 | $0.78 | ||
| Q3 25 | $1.13 | $2.26 | ||
| Q2 25 | $0.36 | $1.76 | ||
| Q1 25 | $0.69 | $1.10 | ||
| Q4 24 | $-0.45 | $0.72 | ||
| Q3 24 | $-1.27 | $2.12 | ||
| Q2 24 | $-0.14 | $1.71 | ||
| Q1 24 | $0.82 | $0.95 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $215.7M |
| 総負債低いほど良い | — | $3.3B |
| 株主資本純資産 | $540.7M | $3.6B |
| 総資産 | $1.4B | $10.2B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.93× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $215.7M | ||
| Q3 25 | $262.6M | $333.2M | ||
| Q2 25 | $217.8M | $474.5M | ||
| Q1 25 | $149.8M | $634.5M | ||
| Q4 24 | $144.9M | $368.9M | ||
| Q3 24 | $145.0M | $427.9M | ||
| Q2 24 | $240.1M | $169.6M | ||
| Q1 24 | $228.6M | $157.6M |
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $3.6B | ||
| Q3 25 | $505.8M | $3.5B | ||
| Q2 25 | $436.8M | $3.4B | ||
| Q1 25 | $418.6M | $3.3B | ||
| Q4 24 | $403.7M | $3.3B | ||
| Q3 24 | $405.9M | $3.3B | ||
| Q2 24 | $455.8M | $3.2B | ||
| Q1 24 | $452.0M | $2.9B |
| Q4 25 | $1.4B | $10.2B | ||
| Q3 25 | $1.4B | $10.1B | ||
| Q2 25 | $1.3B | $9.9B | ||
| Q1 25 | $1.3B | $9.6B | ||
| Q4 24 | $1.3B | $9.2B | ||
| Q3 24 | $1.3B | $9.1B | ||
| Q2 24 | $920.8M | $8.7B | ||
| Q1 24 | $914.5M | $8.3B |
| Q4 25 | — | 0.93× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.92× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $137.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $-216.2M |
| FCFマージンFCF / 売上 | 11.8% | -60.0% |
| 設備投資強度設備投資 / 売上 | 0.5% | 98.3% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 3.16× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $-577.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $137.8M | ||
| Q3 25 | $44.1M | $162.8M | ||
| Q2 25 | $75.8M | $176.9M | ||
| Q1 25 | $35.0M | $124.3M | ||
| Q4 24 | $15.9M | $136.4M | ||
| Q3 24 | $12.5M | $201.9M | ||
| Q2 24 | $17.4M | $146.4M | ||
| Q1 24 | $18.3M | $109.7M |
| Q4 25 | $29.1M | $-216.2M | ||
| Q3 25 | $38.0M | $-127.9M | ||
| Q2 25 | $71.8M | $-156.4M | ||
| Q1 25 | $32.5M | $-77.0M | ||
| Q4 24 | $13.5M | $-48.9M | ||
| Q3 24 | $7.7M | $-16.1M | ||
| Q2 24 | $13.0M | $-199.6M | ||
| Q1 24 | $13.7M | $-150.3M |
| Q4 25 | 11.8% | -60.0% | ||
| Q3 25 | 16.7% | -24.3% | ||
| Q2 25 | 34.0% | -34.8% | ||
| Q1 25 | 16.5% | -18.7% | ||
| Q4 24 | 7.1% | -13.0% | ||
| Q3 24 | 5.2% | -3.0% | ||
| Q2 24 | 9.4% | -45.1% | ||
| Q1 24 | 10.0% | -36.0% |
| Q4 25 | 0.5% | 98.3% | ||
| Q3 25 | 2.7% | 55.2% | ||
| Q2 25 | 1.9% | 74.2% | ||
| Q1 25 | 1.3% | 49.0% | ||
| Q4 24 | 1.3% | 49.3% | ||
| Q3 24 | 3.2% | 41.0% | ||
| Q2 24 | 3.2% | 78.2% | ||
| Q1 24 | 3.3% | 62.2% |
| Q4 25 | 1.10× | 3.16× | ||
| Q3 25 | 1.66× | 1.31× | ||
| Q2 25 | 8.87× | 1.85× | ||
| Q1 25 | 2.23× | 2.08× | ||
| Q4 24 | — | 3.60× | ||
| Q3 24 | — | 1.78× | ||
| Q2 24 | — | 1.63× | ||
| Q1 24 | 1.00× | 2.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
IDA
| Retailrevenues | $323.0M | 90% |
| Transmissionserviceswheeling | $18.6M | 5% |
| Energyefficiencyprogramrevenues | $11.7M | 3% |
| Wholesaleenergysales | $10.5M | 3% |
| Otherrevenues | $9.5M | 3% |
